Episode 324 - Dr. Anath Shalev - Founder and CSO - TIXiMED
Update: 2025-07-09
Description
In this episode of the Diabetes Innovators Series, Rob interviews Dr. Anath
Shalev discussing the recent advancements in TIXiMed's TIX100, an oral
therapy for type 1 diabetes. The conversation covers the successful
completion of a phase one study, the implications of the results, and the
potential impact of TIX100 on diabetes management. Dr. Shalev emphasizes
the importance of addressing beta cell dysfunction and the exciting
metabolic signals observed during the study. The discussion also touches on
the future directions for TIX100 and its role in improving the lives of
diabetes patients.
Chapters
Chapters
00:00 Introduction to TixiMed and TIX100
01:16 Phase One Study Results and Implications
05:22 Metabolic Signals and Future Studies
08:11 The Role of TIX100 in Diabetes Management
09:47 Future Directions and Patient Impact
Resources:
TIXiMED
Dr. Anath Shalev
Shalev discussing the recent advancements in TIXiMed's TIX100, an oral
therapy for type 1 diabetes. The conversation covers the successful
completion of a phase one study, the implications of the results, and the
potential impact of TIX100 on diabetes management. Dr. Shalev emphasizes
the importance of addressing beta cell dysfunction and the exciting
metabolic signals observed during the study. The discussion also touches on
the future directions for TIX100 and its role in improving the lives of
diabetes patients.
Chapters
Chapters
00:00 Introduction to TixiMed and TIX100
01:16 Phase One Study Results and Implications
05:22 Metabolic Signals and Future Studies
08:11 The Role of TIX100 in Diabetes Management
09:47 Future Directions and Patient Impact
Resources:
TIXiMED
Dr. Anath Shalev
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
